Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
NEW YORK - Solas Capital Management LLC has reported a series of transactions involving the sale of shares in Mural Oncology plc, according to a disclosure made to the Irish Takeover Panel. The transactions took place on April 15, 2025, and involved the sale of an aggregate number of 884,999 Mural Oncology ordinary shares through 3,932 separate trades, with prices ranging from $2.90 to $3.20 per share.
The disclosure, made under Rule 8.3 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022, obligates any individual or entity holding an interest in relevant securities representing 1% or more to report their dealings. Solas Capital Management’s dealings come at a time when Mural Oncology has not been identified as being in an offer period, nor has the investment firm disclosed any interests or short positions in cash-settled or stock-settled derivatives related to Mural Oncology.
The Form 8.3 filing also clarified that Solas Capital Management is not making disclosures concerning any other party to the offer and that there are no indemnity or option arrangements, nor any agreements or understandings related to the voting rights of the relevant securities in place.
The details of these transactions were made public on April 23, 2025, by James Cator of Solas Capital Management, with the firm providing contact information for further inquiries.
This disclosure is part of the regulatory requirements that ensure transparency in financial markets, particularly during periods of corporate acquisitions and mergers. It is important for investors to have access to such information which can indicate trading activities by major stakeholders in publicly traded companies.
The information for this report is based on a press release statement from Solas Capital Management LLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.